Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
Holding INSM?
Track your performance easily
INSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.92 - $80.53
Previous CloseN/A
Volume462.72K
Average Volume (3M)1.94M
Market Cap
$14.04B
Enterprise Value$12.38B
Total Cash (Recent Filing)$162.59M
Total Debt (Recent Filing)$54.79M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 20, 2025EPS Estimate
-1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.55
Shares Outstanding178,902,730
10 Day Avg. Volume2,251,338
30 Day Avg. Volume1,936,393
Standard Deviation0.21
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)40.94
Price to Cash Flow (P/CF)-19.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue36.09
Enterprise Value/Gross Profit51.65
Enterprise Value/Ebitda-20.73
Forecast
1Y Price Target
$88.40Price Target Upside12.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Insmed News
PremiumCompany Announcements
Insmed Projects Revenue Growth and Advances Drug Pipeline
PremiumCompany Announcements
Insmed’s Q3 2024: Strong Growth and Strategic Advances
Bulls Say, Bears Say
Bulls Say
Investor ConfidenceManagement's increased conviction in TPIP's potential as a $2 billion plus opportunity.
Market OpportunityA significant unmet need remains in pulmonary arterial hypertension (PAH) despite the availability of MRK's Winrevair, potentially leaving room for drug candidates like INSM’s Treprostinil Palmitil Inhalation Powder (TPIP) in the treatment landscape.
Regulatory ProgressThe application for brenso is expected to receive priority review and is unlikely to require an AdComm, which could expedite its approval process.
Bears Say
Financial PerformanceINSM reported net loss of $220M ($1.27) for 3Q24.
Market SentimentInvestors remain somewhat skeptical of brensocatib's potential, which is currently the biggest drag on sentiment.
Product DevelopmentFDA feedback indicates that confirmatory data from the ongoing phase 3 ENCORE is required for Arikayce's 1L approval, which is seen as a setback.
---
Ownership Overview
1.28% Insiders
35.37% Mutual Funds
0.40% Other Institutional Investors
46.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $21.92 and its highest was $80.53 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $14.04B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Feb 20, 2025 which is in 22 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Oct 31, 2024. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$1.202 by -$0.068.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.17.
How many shares outstanding does Insmed have?
Insmed has 178,902,730 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.27 in its last earnings report, missing expectations of -$1.202. Following the earnings report the stock price went down -4.296%.
Which hedge fund is a major shareholder of Insmed?
Among the largest hedge funds holding Insmed’s share is Baker Bros Advisors LP. It holds Insmed’s shares valued at 322M.
---
Insmed Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.40 (12.67% Upside)
$88.40 (12.67% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 812.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.42%
12-Months-Change
Fundamentals
Return on Equity
-890.75%
Trailing 12-Months
Asset Growth
54.96%
Trailing 12-Months
Company Description
Insmed
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
---
INSM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was generally positive, highlighting significant sales growth, a strong financial position, and progress in drug development. However, concerns about increased cash burn and uncertainties regarding regulatory approvals were noted.Read More>---
INSM Stock 12 Month Forecast
Average Price Target
$88.40
▲(12.67% Upside)
Technical Analysis
Amicus
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering INSM
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+103.81%
assigned a buy rating 14 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +103.81% per trade.
---